Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired MacroGenics, Inc, (“MGNX”) securities or sold MGNX puts between March 7, 2024 and May 9, 2024, inclusive (the “Class Period”).
The complaint alleges that the Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts related to early interim safety data results from the TAMARACK Phase 2 study.
Current Status of Case:
On December 20, 2024, the Court granted Plaintiffs’ Notice of Voluntary Dismissal and closed the case. This action has concluded.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.